CN115236261B - 一种托法替尼中间体纯度的hplc-uv检测方法 - Google Patents
一种托法替尼中间体纯度的hplc-uv检测方法 Download PDFInfo
- Publication number
- CN115236261B CN115236261B CN202210504757.9A CN202210504757A CN115236261B CN 115236261 B CN115236261 B CN 115236261B CN 202210504757 A CN202210504757 A CN 202210504757A CN 115236261 B CN115236261 B CN 115236261B
- Authority
- CN
- China
- Prior art keywords
- tofacitinib
- tofacitinib intermediate
- percent
- purity
- hplc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004012 Tofacitinib Substances 0.000 title claims abstract description 49
- 229960001350 tofacitinib Drugs 0.000 title claims abstract description 49
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 title claims abstract description 49
- 238000000825 ultraviolet detection Methods 0.000 title claims abstract description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000012535 impurity Substances 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000012488 sample solution Substances 0.000 claims abstract description 15
- 239000000126 substance Substances 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims abstract description 10
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000005695 Ammonium acetate Substances 0.000 claims abstract description 9
- 229940043376 ammonium acetate Drugs 0.000 claims abstract description 9
- 235000019257 ammonium acetate Nutrition 0.000 claims abstract description 9
- 238000010828 elution Methods 0.000 claims abstract description 9
- 238000000926 separation method Methods 0.000 claims abstract description 9
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000001514 detection method Methods 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- BSBVJNUGGBQEPO-UHFFFAOYSA-N 1-benzyl-4-methylpiperidin-3-one Chemical compound C1C(=O)C(C)CCN1CC1=CC=CC=C1 BSBVJNUGGBQEPO-UHFFFAOYSA-N 0.000 claims description 2
- -1 octadecyl organosilane Chemical class 0.000 claims description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000741 silica gel Substances 0.000 abstract description 2
- 229910002027 silica gel Inorganic materials 0.000 abstract description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 description 39
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229910052611 pyroxene Inorganic materials 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/89—Inverse chromatography
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210504757.9A CN115236261B (zh) | 2022-05-10 | 2022-05-10 | 一种托法替尼中间体纯度的hplc-uv检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210504757.9A CN115236261B (zh) | 2022-05-10 | 2022-05-10 | 一种托法替尼中间体纯度的hplc-uv检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115236261A CN115236261A (zh) | 2022-10-25 |
CN115236261B true CN115236261B (zh) | 2024-04-19 |
Family
ID=83667637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210504757.9A Active CN115236261B (zh) | 2022-05-10 | 2022-05-10 | 一种托法替尼中间体纯度的hplc-uv检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115236261B (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104678001A (zh) * | 2013-12-03 | 2015-06-03 | 重庆医药工业研究院有限责任公司 | 一种用液相色谱法分离测定枸橼酸托法替尼及其光学异构体的方法 |
CN106146517A (zh) * | 2016-06-20 | 2016-11-23 | 山东大学 | 一种枸橼酸托法替尼的合成方法 |
WO2018172821A1 (en) * | 2017-03-23 | 2018-09-27 | Phalanx Labs Private Limited | Novel tofacitinib addition salts and process for the preparation thereof |
CN108822112A (zh) * | 2018-08-13 | 2018-11-16 | 山东罗欣药业集团恒欣药业有限公司 | 一种托法替尼化合物的制备方法 |
WO2020183295A1 (en) * | 2019-03-13 | 2020-09-17 | Intas Pharmaceuticals Ltd. | Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof |
CN111983056A (zh) * | 2020-07-28 | 2020-11-24 | 安徽联创生物医药股份有限公司 | 一种用hplc分离测定托法替尼中间体有关物质的方法 |
CN112697912A (zh) * | 2020-12-14 | 2021-04-23 | 上海博悦生物科技有限公司 | 一种检测枸橼酸托法替布中间体及其相关杂质的方法 |
CN113125587A (zh) * | 2019-12-30 | 2021-07-16 | 成都百裕制药股份有限公司 | 一种托法替尼中间体及其对映异构体的检测方法 |
CN113930404A (zh) * | 2021-10-13 | 2022-01-14 | 浙江乐普药业股份有限公司 | 一种酶法合成手性枸橼酸托法替布中间体的方法 |
-
2022
- 2022-05-10 CN CN202210504757.9A patent/CN115236261B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104678001A (zh) * | 2013-12-03 | 2015-06-03 | 重庆医药工业研究院有限责任公司 | 一种用液相色谱法分离测定枸橼酸托法替尼及其光学异构体的方法 |
CN106146517A (zh) * | 2016-06-20 | 2016-11-23 | 山东大学 | 一种枸橼酸托法替尼的合成方法 |
WO2018172821A1 (en) * | 2017-03-23 | 2018-09-27 | Phalanx Labs Private Limited | Novel tofacitinib addition salts and process for the preparation thereof |
CN108822112A (zh) * | 2018-08-13 | 2018-11-16 | 山东罗欣药业集团恒欣药业有限公司 | 一种托法替尼化合物的制备方法 |
WO2020183295A1 (en) * | 2019-03-13 | 2020-09-17 | Intas Pharmaceuticals Ltd. | Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof |
CN113125587A (zh) * | 2019-12-30 | 2021-07-16 | 成都百裕制药股份有限公司 | 一种托法替尼中间体及其对映异构体的检测方法 |
CN111983056A (zh) * | 2020-07-28 | 2020-11-24 | 安徽联创生物医药股份有限公司 | 一种用hplc分离测定托法替尼中间体有关物质的方法 |
CN112697912A (zh) * | 2020-12-14 | 2021-04-23 | 上海博悦生物科技有限公司 | 一种检测枸橼酸托法替布中间体及其相关杂质的方法 |
CN113930404A (zh) * | 2021-10-13 | 2022-01-14 | 浙江乐普药业股份有限公司 | 一种酶法合成手性枸橼酸托法替布中间体的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN115236261A (zh) | 2022-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110133149B (zh) | 一种分离测定lcz696及其杂质的方法 | |
JP4887286B2 (ja) | エナンチオマーの分離用組成物及び方法 | |
CN111239299B (zh) | 一种分离测定帕博西尼及其杂质的方法 | |
CN115236261B (zh) | 一种托法替尼中间体纯度的hplc-uv检测方法 | |
CN103675110A (zh) | 一种四溴双酚a成分的分离与分析测定方法 | |
CN107271592B (zh) | 一种盐酸替吡拉西与其相关杂质完全分离的液相色谱纯度检测方法 | |
CN110174467B (zh) | 一种高效液相色谱法分析分离2,4-二氰基-3-异丁基戊二酰胺的方法 | |
CN112213402B (zh) | (3r,4r)-1-苄基-n,4-二甲基哌啶-3-胺二盐酸盐及其异构体的检测方法 | |
CN107941946B (zh) | 一种富马酸沃诺拉赞的检测方法 | |
CN108169399B (zh) | 去甲氨噻肟酸乙酯粗品中杂质的分离方法 | |
CN101929988A (zh) | 一种用高效液相色谱法测定非布索坦有关物质的方法 | |
CN112834637B (zh) | 反相高效液相色谱检测帕拉米韦中间体i的方法 | |
CN107490630B (zh) | 7-氟-4-羟基喹唑啉的分析检测方法 | |
CN107490631A (zh) | 一种阿法替尼中间体的分析检测方法 | |
CN107490629A (zh) | 一种阿法替尼中间体的高效液相色谱分析方法 | |
CN112209882A (zh) | 左奥硝唑杂质c及其制备方法和用途 | |
CN109917057A (zh) | 一种分离分析泮托拉唑硫醚有关物质的hplc方法 | |
CN114965738B (zh) | 一种2,4-二氨基-6-羟基嘧啶起始物料纯度的hplc-uv检测方法 | |
CN114324637B (zh) | 美罗培南中三种潜在基因毒性杂质的检测方法 | |
CN111257441B (zh) | 一种帕瑞昔布钠合成工艺杂质的检测方法 | |
CN116559354B (zh) | 一种采用反相色谱法检测卡非佐米对映异构体的方法 | |
CN107490646A (zh) | 一种用高效液相色谱法测定阿法替尼中间体含量的方法 | |
Boháček | Isocratic separation of DNA bases and deoxyribonucleosides by high-performance liquid chromatography on anex OSTION | |
CN109212116A (zh) | 高效液相色谱法分离测定比拉斯汀中间体化学纯度的方法 | |
CN104515815A (zh) | L-谷氨酸二乙酯的分析检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Mei Qing Inventor after: Hu Jin Inventor after: Guan Danyingzi Inventor after: Chai Jinzhu Inventor before: Chai Jinzhu Inventor before: Mei Qing Inventor before: Hu Jin Inventor before: Guan Danyingzi |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240325 Address after: C6324, C6522, C6523, C6524, Building C6, Optics Valley Biological City, No. 666, Gaoxin Avenue, Donghu New Technology Development Zone, Hongshan District, Wuhan, Hubei 430200 Applicant after: Wuhan Haite Bioinnovation Pharmaceutical Research Co.,Ltd. Country or region after: China Address before: 448000 No. 1, Xinghua Third Road, Duodao District, Jingmen City, Hubei Province Applicant before: Hanrui Pharmaceutical (Jingmen) Co.,Ltd. Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant |